Lipum AB Logo

Lipum AB

Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.

LIPUM | ST

Overview

Corporate Details

ISIN(s):
SE0015660899 (+1 more)
LEI:
549300V7JL0004BHBD93
Country:
Sweden
Address:
Tvistevägen 48 C, 907 36 Umeå
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Lipum AB is a clinical-stage biopharmaceutical company specializing in the discovery and development of novel treatments for chronic inflammatory diseases. The company's lead candidate, SOL-116, is a first-in-class humanized antibody that offers a unique mechanism of action by targeting the protein bile salt-stimulated lipase (BSSL). Lipum's primary goal is to address unmet medical needs and improve the quality of life for patients suffering from conditions such as rheumatoid arthritis (RA). The company has successfully completed its First-in-Human (FIH) Phase I clinical trial for SOL-116, with findings supporting continued development towards a potential new therapy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Lipum AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Lipum AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Lipum AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-14 Peter Hovstadius Other Sell 2,000 28,260.00 SEK
2025-04-14 Peter Hovstadius Other Sell 1,500 22,770.00 SEK
2025-04-14 Peter Hovstadius Other Sell 1,500 21,030.00 SEK

Peer Companies

Company Country Ticker View
Canopy Growth Corp Logo
Produces diverse cannabis products for medical and recreational markets globally.
United States of America CGC
Cantourage Group SE Logo
A European platform producing and distributing medical cannabis products to pharmacies.
Germany HIGH
CAPRICOR THERAPEUTICS, INC. Logo
Develops cell and exosome-based therapeutics for rare diseases like Duchenne muscular dystrophy.
United States of America CAPR
CAREGEN CO.,LTD. Logo
Develops patented peptides and growth factors for medical aesthetics, pharma, and anti-aging markets.
South Korea 214370
Caribou Biosciences, Inc. Logo
Uses CRISPR genome editing to create off-the-shelf CAR-T cell therapies for cancer.
United States of America CRBU
Carisma Therapeutics Inc. Logo
Developing engineered macrophage (CAR-M) therapies for solid tumors and autoimmune diseases.
United States of America CARM
Cartesian Therapeutics, Inc. Logo
Pioneering mRNA-engineered cell therapies to treat autoimmune diseases.
United States of America RNAC
CASI Pharmaceuticals, Inc. Logo
Develops and commercializes drugs for oncology, transplant, and autoimmune disease.
United States of America CASI
CASSAVA SCIENCES INC Logo
Clinical-stage biotech developing oral drug simufilam for CNS disorders like TSC-related epilepsy.
United States of America SAVA
CATALYST PHARMACEUTICALS, INC. Logo
Advancing therapies for rare neuromuscular and neurological diseases like LEMS.
United States of America CPRX

Talk to a Data Expert

Have a question? We'll get back to you promptly.